[ad_1]
Related Posts
The National Center for Research in Epidemiology and Microbiology N. pag. Gamalia, affiliated with the Ministry of Health and producer of the vaccine in association with Russia’s Direct Investment Fund, said that the second phase of clinical trials of the vaccine showed an effectiveness of 91.4% on day 28 after the first dose and more than 95% after 42 days.
These positive results were obtained during the analysis of data from random groups that included around 40 thousand volunteers, which is the largest in the history of global trials to develop vaccines. The Russian researchers were able to produce the vaccine in dry form by freezing at low temperatures, while it is stored at temperatures between + 2 and + 8 degrees Celsius, which allows the vaccine to be distributed worldwide in all hard-to-reach areas, including the tropics and warm tropics.
Subscribe to «News» on YouTube here